Other OTC - Delayed Quote • USD
CohBar, Inc. (CWBR)
At close: May 13 at 9:36 AM EDT
Key Executives
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Pinchas Cohen Dean, M.D. | Founder & Member of Scientific Advisory Board | 65.25k | -- | 1957 |
Dr. Nir Yacov Barzilai M.D. | Founder & Member of Scientific Advisory Board | 65.25k | -- | 1956 |
Dr. John M. Amatruda M.D., Ph.D. | Co-Founder | 31.5k | -- | 1946 |
Ms. Jordyn Tarazi | Director of Investor Relations | -- | -- | -- |
CohBar, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
Corporate Governance
CohBar, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Nov 27, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 13, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 01, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Oct 25, 2023425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsSee Full Filing
- Oct 06, 2023425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsSee Full Filing
Upcoming Events
May 14, 2024 - May 17, 2024
CohBar, Inc. Earnings Call
Related Tickers
NGEN.V NervGen Pharma Corp.
2.1000
+1.45%
NGENF NervGen Pharma Corp.
1.5500
+1.31%
MDNAF Medicenna Therapeutics Corp.
1.8300
+1.10%
HSTO Histogen Inc.
0.2000
0.00%
ELOX Eloxx Pharmaceuticals, Inc.
0.9000
-1.76%
CYP.AX Cynata Therapeutics Limited
0.2450
+2.08%
SNTI Senti Biosciences, Inc.
0.3620
-0.71%
APTO Aptose Biosciences Inc.
1.1800
-4.07%
ARMP Armata Pharmaceuticals, Inc.
3.2100
+3.84%
GTBP GT Biopharma, Inc.
3.2500
-1.81%